Rana McKay, MD

Rana McKay, MD, is a medical oncologist at the University of California, San Diego Moores Cancer Center.

Articles by Rana McKay, MD

Michael Morris, MDRoundtable | November 16, 2023
The panel shares insights on future advancements in the field.
View More
Michael Morris, MDRoundtable | November 16, 2023
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
Michael Morris, MDRoundtable | November 16, 2023
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
Michael Morris, MDRoundtable | November 16, 2023
The panel talks "pearls of wisdom" with radioligand therapy.
Michael Morris, MDRoundtable | November 16, 2023
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
Michael Morris, MDRoundtable | November 16, 2023
The panel discussed initial access issues with radioligand therapy, as well as interdisciplinary team collaboration.
Rana McKay, MDUromigos Live 2023 | September 25, 2023
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Chung-Han Lee, MD, PhDASCO 2023 | August 23, 2023
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | May 16, 2023
Drs. McKay and Braun wrap up their discussion with comments on which novel therapies hold the most promise in advanced RCC.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | May 16, 2023
Drs. McKay and Braun share their strategy for strategy for patient selection in the clinic, including first- and second-line.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | May 16, 2023
Drs. McKay and Braun highlights novel RCC biomarkers being developed, including imaging-, pathology-, and blood-based ones.
David Braun, MD, PhDAdvanced Renal Cell Carcinoma | May 16, 2023
Dr. McKay speaks with Dr. Braun on the current biomarker landscape for RCC and how biomarkers have shaped treatment.
Rana McKay, MDAdvanced Urothelial Carcinoma | April 24, 2023
Dr Rana McKay shares how the approval of enfortumab vedotin plus pembrolizumab impacts patients with advanced UC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 9, 2023
Dr. McKay explains how radiation therapy and modalities fit into the treatment paradigm for RCC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 9, 2023
Dr. McKay summarizes the novel therapies or optimal sequencing patterns that are close to entering the mRCC treatment space.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 9, 2023
Dr. McKay offers an overview of the second-line and later-line therapy options after progression for metastatic RCC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 9, 2023
Dr. McKay highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk mRCC.
Rana McKay, MDAdvanced Renal Cell Carcinoma | March 9, 2023
Dr. Rana McKay details how advanced or mRCC is currently managed and how the treatment paradigm has evolved since 2018.